Characterization and initial demonstration of in vivo efficacy of a novel heat-activated metalloenediyne anti-cancer agent.

Autor: Garrett J; Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA., Metzger E; Department of Chemistry, Indiana University, Bloomington, IN, USA., Dewhirst MW; Department of Radiation Oncology, Duke University School of Medicine, Durham, NC, USA., Pollok KE; In Vivo Therapeutics Core, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA., Turchi JJ; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA., Le Poole IC; Department of Dermatology, Northwestern University, Chicago, IL, USA., Couch K; Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA., Lew L; Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA., Sinn A; In Vivo Therapeutics Core, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA., Zaleski JM; Department of Chemistry, Indiana University, Bloomington, IN, USA., Dynlacht JR; Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.
Jazyk: angličtina
Zdroj: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group [Int J Hyperthermia] 2022; Vol. 39 (1), pp. 405-413.
DOI: 10.1080/02656736.2021.2024280
Abstrakt: Background: Enediynes are anti-cancer agents that are highly cytotoxic due to their propensity for low thermal activation of radical generation. The diradical intermediate produced from Bergman cyclization of the enediyne moiety may induce DNA damage and cell lethality. The cytotoxicity of enediynes and difficulties in controlling their thermal cyclization has limited their clinical use. We recently showed that enediyne toxicity at 37 °C can be mitigated by metallation, but cytotoxic effects of 'metalloenediynes' on cultured tumor cells are potentiated by hyperthermia. Reduction of cytotoxicity at normothermia suggests metalloenediynes will have a large therapeutic margin, with cell death occurring primarily in the heated tumor. Based on our previous in vitro findings, FeSO 4 -PyED, an Fe co-factor complex of ( Z )-N,N'-bis[1-pyridin-2-yl-meth-( E )-ylidene]oct-4-ene-2,6-diyne-1,8-diamine, was prioritized for further in vitro and in vivo testing in normal human melanocytes and melanoma cells.
Methods: Clonogenic survival, apopotosis and DNA binding assays were used to determine mechanisms of enhancement of FeSO 4 -PyED cytotoxicity by hyperthermia. A murine human melanoma xenograft model was used to assess in vivo efficacy of FeSO 4 -PyED at 37 or 42.5 °C.
Results: FeSO 4 -PyED is a DNA-binding compound. Enhancement of FeSO 4 -PyED cytotoxicity by hyperthermia in melanoma cells was due to Bergman cyclization, diradical formation, and increased apoptosis. Thermal enhancement, however, was not observed in melanocytes. FeSO 4 -PyED inhibited tumor growth when melanomas were heated during drug treatment, without inducing normal tissue damage.
Conclusion: By leveraging the unique thermal activation properties of metalloenediynes, we propose that localized moderate hyperthermia can be used to confine the cytotoxicity of these compounds to tumors, while sparing normal tissue.
Databáze: MEDLINE
Externí odkaz: